Zim Laboratories Limited (ZIMLAB) - Net Assets

Latest as of September 2025: Rs2.51 Billion INR ≈ $27.18 Million USD

Based on the latest financial reports, Zim Laboratories Limited (ZIMLAB) has net assets worth Rs2.51 Billion INR (≈ $27.18 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs4.70 Billion ≈ $50.84 Million USD) and total liabilities (Rs2.19 Billion ≈ $23.66 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ZIMLAB asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Rs2.51 Billion
% of Total Assets	53.46%
Annual Growth Rate	7.42%
5-Year Change	56.91%
10-Year Change	156.5%
Growth Volatility	9.85

Zim Laboratories Limited - Net Assets Trend (2013–2025)

This chart illustrates how Zim Laboratories Limited's net assets have evolved over time, based on quarterly financial data. Also explore Zim Laboratories Limited balance sheet assets for the complete picture of this company's asset base.

Annual Net Assets for Zim Laboratories Limited (2013–2025)

The table below shows the annual net assets of Zim Laboratories Limited from 2013 to 2025. For live valuation and market cap data, see Zim Laboratories Limited market capitalisation.

Year	Net Assets	Change
2025-03-31	Rs2.52 Billion ≈ $27.28 Million	+5.65%
2024-03-31	Rs2.39 Billion ≈ $25.82 Million	+19.17%
2023-03-31	Rs2.00 Billion ≈ $21.67 Million	+14.02%
2022-03-31	Rs1.76 Billion ≈ $19.00 Million	+9.31%
2021-03-31	Rs1.61 Billion ≈ $17.38 Million	+4.50%
2020-03-31	Rs1.54 Billion ≈ $16.64 Million	+1.79%
2019-03-31	Rs1.51 Billion ≈ $16.34 Million	+10.63%
2018-03-31	Rs1.37 Billion ≈ $14.77 Million	+15.44%
2017-03-31	Rs1.18 Billion ≈ $12.80 Million	+20.33%
2016-03-31	Rs983.37 Million ≈ $10.63 Million	+4.38%
2015-03-31	Rs942.10 Million ≈ $10.19 Million	-18.80%
2014-03-31	Rs1.16 Billion ≈ $12.55 Million	+8.62%
2013-03-31	Rs1.07 Billion ≈ $11.55 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Zim Laboratories Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 232.8% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (March 2025)

Component	Amount	Percentage
Retained Earnings	Rs1.69 Billion	67.02%
Common Stock	Rs487.26 Million	19.32%
Other Comprehensive Income	Rs264.24 Million	10.48%
Other Components	Rs80.30 Million	3.18%
Total Equity	Rs2.52 Billion	100.00%

Zim Laboratories Limited Competitors by Market Cap

The table below lists competitors of Zim Laboratories Limited ranked by their market capitalization.

Company	Market Cap
Magnitude International Ltd Ordinary Shares NASDAQ:MAGH	$46.36 Million
Molinos Juan Semino SA BA:SEMI	$46.37 Million
Tolins Tyres Ltd NSE:TOLINS	$46.38 Million
Xplus SA WAR:XPL	$46.39 Million
Sequana Medical NV BR:SEQUA	$46.31 Million
Yuasa Battery (Thailand) Public Company Limited BK:YUASA	$46.29 Million
Davolink Inc. KQ:340360	$46.29 Million
2S Metal Public Company Limited BK:2S	$46.29 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Zim Laboratories Limited's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 2,387,458,000 to 2,522,375,000, a change of 134,917,000 (5.7%).
Net income of 121,652,000 contributed positively to equity growth.
Dividend payments of 569,000 reduced retained earnings.
Other comprehensive income increased equity by 29,266,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	Rs121.65 Million	+4.82%
Dividends Paid	Rs569.00K	-0.02%
Other Comprehensive Income	Rs29.27 Million	+1.16%
Other Changes	Rs-15.43 Million	-0.61%
Total Change	Rs-	5.65%

Book Value vs Market Value Analysis

This analysis compares Zim Laboratories Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.70x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 3.40x to 1.70x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2013-03-31	Rs25.83	Rs87.94	x
2014-03-31	Rs24.18	Rs87.94	x
2015-03-31	Rs19.37	Rs87.94	x
2016-03-31	Rs20.22	Rs87.94	x
2017-03-31	Rs24.33	Rs87.94	x
2018-03-31	Rs28.08	Rs87.94	x
2019-03-31	Rs31.03	Rs87.94	x
2020-03-31	Rs31.59	Rs87.94	x
2021-03-31	Rs33.02	Rs87.94	x
2022-03-31	Rs36.06	Rs87.94	x
2023-03-31	Rs41.12	Rs87.94	x
2024-03-31	Rs49.00	Rs87.94	x
2025-03-31	Rs51.84	Rs87.94	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Zim Laboratories Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 4.82%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 3.25%
• Asset Turnover: 0.79x
• Equity Multiplier: 1.87x
Recent ROE (4.82%) is below the historical average (6.07%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2013	8.92%	5.15%	0.85x	2.04x	Rs-11.57 Million
2014	8.74%	4.47%	0.86x	2.27x	Rs-14.62 Million
2015	-22.94%	-8.25%	0.99x	2.81x	Rs-310.29 Million
2016	5.18%	1.93%	1.03x	2.60x	Rs-47.36 Million
2017	15.71%	8.10%	0.89x	2.19x	Rs67.53 Million
2018	13.99%	7.19%	0.89x	2.18x	Rs54.50 Million
2019	10.15%	4.70%	0.99x	2.17x	Rs2.30 Million
2020	2.14%	1.26%	0.80x	2.11x	Rs-120.86 Million
2021	4.55%	2.38%	0.95x	2.02x	Rs-87.58 Million
2022	8.28%	4.40%	0.97x	1.94x	Rs-30.21 Million
2023	12.20%	6.13%	1.17x	1.70x	Rs44.00 Million
2024	7.22%	4.69%	0.82x	1.87x	Rs-66.28 Million
2025	4.82%	3.25%	0.79x	1.87x	Rs-130.59 Million

Industry Comparison

This section compares Zim Laboratories Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $23,713,303,062
Average return on equity (ROE) among peers: 8.81%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Zim Laboratories Limited (ZIMLAB)	Rs2.51 Billion	8.92%	0.87x	$46.35 Million
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS)	$988.60 Million	6.59%	1.36x	$27.93 Million
Aarti Drugs Limited (AARTIDRUGS)	$6.52 Billion	21.67%	1.42x	$371.43 Million
Aarti Pharmalabs Limited (AARTIPHARM)	$19.90 Billion	13.69%	0.46x	$725.68 Million
Abbott India Limited (ABBOTINDIA)	$36.99 Billion	32.48%	0.40x	$5.85 Billion
Ajanta Pharma Limited (AJANTPHARM)	$1.16 Billion	12.69%	1.32x	$3.81 Billion
Akums Drugs and Pharmaceutical (AKUMS)	$6.25 Billion	-40.39%	3.91x	$906.19 Million
Alkem Laboratories Limited (ALKEM)	$88.47 Billion	18.60%	0.59x	$6.98 Billion
Amrutanjan Health Care Limited (AMRUTANJAN)	$1.46 Billion	16.82%	0.29x	$178.52 Million
Alembic Pharmaceuticals Limited (APLLTD)	$51.90 Billion	11.24%	0.50x	$1.60 Billion
Aurobindo Pharma Limited (AUROPHARMA)	$23.50 Billion	-5.26%	1.65x	$8.73 Billion

About Zim Laboratories Limited

NSE:ZIMLAB India Drug Manufacturers - Specialty & Generic

Market Cap

$46.35 Million

Rs4.29 Billion INR

Market Cap Rank

#22166 Global

#1225 in India

Share Price

Rs87.94

Change (1 day)

+3.05%

52-Week Range

Rs60.26 - Rs120.82

All Time High

Rs149.00